On December 21, a delegation from our company, including Chairman Shi Yuanyuan, Chief Scientist Professor Wang Jianxun, Marketing Department Head Sun Rui, and R&D Department Head Zhao Lijun, visited the Hong Kong Institute of Biotechnology (HKIB) for exchange. Dr. Jiang Gina, Director of HKIB, Deputy General Manager Dr. C.K. Wong, and Deputy General Manager Dr. Maggie Z.Y. Chow warmly received them and held symposium discussions, delving into future directions for cooperation.

During the symposium, our Chairman Shi Yuanyuan first introduced in detail the development history of Shenzhen Cell Valley, the core team, the advantages of retroviral vectors for preparing CAR-T cells, the four major services — viral products, cell products, regulatory submission assistance, and talent cultivation, GMP-grade production facilities, clinical application progress, major technological breakthroughs, and overall corporate strength. The Hong Kong Institute of Biotechnology team introduced the GMP construction status for advanced therapy products (ATP). Professor Shi stated that Shenzhen Cell Valley currently has 5,000 square meters of GMP laboratories meeting international standards, with multiple production lines for viral vectors and CAR-T cell products, and an R&D and production team mastering the first industrial-grade retroviral vector technology (PackRV-SS system) in China. The company consistently focuses on optimizing processes and pioneering technological innovations, while continuously strengthening cooperation with research institutes, pharmaceutical companies, and universities to establish upstream and downstream industry chain linkages and achieve resource complementarity. Significant progress has currently been made in scientific research, clinical applications, and industrial production. Dr. Jiang Gina, Director of HKIB, highly commended our company's profound technological expertise, scientific research innovation spirit, and talent cultivation capabilities, and expressed hope for in-depth cooperation with Shenzhen Cell Valley, leveraging the advantages of low cost and high capacity of retroviral vectors in industrial production to join forces with Shenzhen Cell Valley, actively connect with the Hong Kong innovation ecosystem resources in industry-academia-research, and promote exchanges and cooperation in the biomedical industries of both cities.

This exchange visit has laid a good foundation for cooperation between the two parties. Shenzhen Cell Valley and the Hong Kong Institute of Biotechnology will collaborate on establishing a retroviral vector-based cell preparation industry chain, creating a talent cultivation mechanism for the industry, and jointly applying for Guangdong-Hong Kong and Shenzhen-Hong Kong cooperation projects, collectively making positive contributions to the development of the biomedical field in the Guangdong-Hong Kong-Macao Greater Bay Area.

Hong Kong Institute of Biotechnology Limited (hereinafter referred to as "HKIB") is a wholly-owned research unit of The Chinese University of Hong Kong, established in 1988 with a donation from The Hong Kong Jockey Club Charities Trust. HKIB is committed to promoting and encouraging the development of the biotechnology and Chinese medicine industries in Hong Kong. Through funding from the Innovation and Technology Commission of the HKSAR Government, HKIB has been able to acquire more and newer research and production equipment in these two areas over the past few years.

HKIB provides extensive infrastructure, product and technology development, contract manufacturing, Good Manufacturing Practice (GMP) consulting and training services. Leveraging our professional expertise, we actively participate in process development and product commercialization. We also collaborate with industry partners to apply for government-funded projects and develop new technologies and products in the fields of biotechnology, pharmaceuticals, and Chinese medicine.

As a unit affiliated with The Chinese University of Hong Kong and a designated local public research institution by the Innovation and Technology Commission, HKIB can bring together academia, government, and industry to jointly promote the development of Hong Kong's biotechnology and Chinese medicine industries. As a non-profit organization, HKIB charges fees equivalent to the cost for its services.